RM Magazine
Drug development
Patients begin CAR-T cell treatment trial
The Royal Marsden has recently been approved by NHS England to deliver a new type of immunotherapy for patients with relapsed or refractory diffuse large B-cell lymphoma.
Read more
Drug development
70 years of innovation at The Royal Marsden
As the NHS celebrates its 70th birthday in July 2018, we take a look back at what The Royal Marsden has achieved in the fields of drug development, radiotherapy and surgery during that time.
Read more
Drug development
Carbon copies
The Royal Marsden has led the drive to bring biosimilars – near-identical replicas of vital drugs that are just as effective as the originals, yet cost far less – to more cancer patients
Read more
Drug development
Celebrating a decade of pioneering drug development
Staff at the Oak Foundation Drug Development Unit (DDU) have celebrated a decade of innovation by showcasing the work of the unit to patients, relatives and hospital colleagues at a special evening event
Read more
Drug development
Q&A: Targeted drug trial
Dr Irene Chong, Consultant Clinical Oncologist, discusses ibrutinub and oesophageal cancers
Read more